Forian Inc (FORA) Fair Value & Analysis
Healthcare · US · Market cap $67.8M
Forian Inc
FORA · US
Fair value as of: Jul 16, 2026
From 7 valuation models · updated 26 days ago
Fair value updated Jul 16, 2026, revised from $4.29 to $1.61 (−62.5%) since Jun 24, 2026. Share price +1.5% over the past month.
A solid business, but screening 41% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case ($1.97). The favourable scenario is already priced in.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.
How to read this chart
60‑month range $1.75 – $14.04 · fair‑value band $1.25 – $1.97 · the $2.74 price screens above the $1.61 fair value. Dashed = 300-day average. As of Jul 16, 2026.
Analysis
Forian Inc (FORA) currently trades at $2.74, while our model-based Fair Value estimate is $1.61, implying the stock looks roughly 41.2% overvalued today. The Quality Score stands at 60/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Forian Inc generated revenue of $30.1M at a net margin of -17.0%. Revenue declined 2.9% year over year. It earns a return on equity of -18.0%. The balance sheet holds a net cash position of $12.9M. Fundamentals as of Jul 16, 2026
Our scenario range runs from $1.25 (bear case) to $1.97 (bull case); at $2.74, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 7% below its 52-week high and 67% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -53% fair-value upside, at -41%, FORA screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 7 models by family
Widest divergence: Growth DCF ($1.27) versus Asset-Based ($0.6400). Highest evidence: Growth DCF (80).
Notify me when FORA reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 16, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 63 · Market factors (momentum, volatility) 66
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Forian Inc. provides a suite of data management capabilities and proprietary information and analytics solutions to optimize and measure operational, clinical and financial performance. It develops commercial, real-world evidence (RWE), and market access solutions and proprietary data-driven insights.
Full company description
Forian Inc. provides a suite of data management capabilities and proprietary information and analytics solutions to optimize and measure operational, clinical and financial performance. It develops commercial, real-world evidence (RWE), and market access solutions and proprietary data-driven insights. The company's subscription and services-based solutions serve the life sciences, pharmaceutical services, healthcare payer, and provider and financial services industries. Forian Inc. was founded in 2020 and is headquartered in Newtown, Pennsylvania. Forian Inc. operates as a subsidiary of 2025 Acquisition Company, LLC.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Forian Inc reported revenue of $30.3M in FY2025 versus $16.9M in FY2021, a compound +15.7%/yr. Reported net income was −$2.9M in FY2025.
FORA screens 41% overvalued. Compare with Veeva Systems Inc →
Peer Group
Health Information Services · 125 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Health Information Services median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $190.12 | $95.12 | -50% |
| Pro Medicus Limited PME | A$194.84 | A$23.74 | -88% |
| BrightSpring Health Services, Inc BTSG | $68.16 | $21.31 | -69% |
| HealthEquity, Inc HQY | $97.67 | $56.63 | -42% |
| Hinge Health, Inc HNGE | $88.80 | $24.03 | -73% |
| 10x Genomics, Inc TXG | $45.75 | $17.18 | -62% |
| Waystar Holding WAY | $22.69 | $12.86 | -43% |
| Doximity, Inc DOCS | $22.21 | $17.18 | -23% |
| Privia Health Group PRVA | $28.10 | $5.30 | -81% |
| Inventurus Knowledge Solutions Limited IKS | ₹1,846 | ₹860.28 | -53% |
Compare Forian Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Forian Inc (FORA) overvalued or undervalued?
What is the fair value of FORA?
What is the quality score of FORA?
What is the revenue of Forian Inc (FORA)?
What is the net profit margin of FORA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Forian Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.